Literature DB >> 14570228

Keratinocyte carcinoma.

Michael R Albert1, Martin A Weinstock.   

Abstract

Keratinocyte carcinoma is by far the most common cancer in the United States. Basal cell carcinomas and squamous cell carcinomas account for approximately 80% and 20% of cases of KC, respectively. The term nonmelanoma skin cancer is commonly used to refer to squamous cell carcinomas and basal cell carcinomas; however, other types of nonmelanoma skin cancer, such as adnexal tumors and sarcomas, are less common and differ in their cell type, behavior, and epidemiologic features from KC. Primary care clinicians are well positioned to diagnose KC and to educate patients about preventive measures such as sun protection and self-examination. Here we review epidemiologic data and strategies for prevention, diagnosis, and clinical management of KC.

Entities:  

Mesh:

Year:  2003        PMID: 14570228     DOI: 10.3322/canjclin.53.5.292

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  21 in total

1.  Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma.

Authors:  Ting Liu; Zeyuan Lei; ZhengYing Pan; Yu Chen; Xiang Li; TongChun Mao; Qian He; Dongli Fan
Journal:  Tumour Biol       Date:  2013-12-20

Review 2.  The 1,25-dihydroxyvitamin D3-independent actions of the vitamin D receptor in skin.

Authors:  Diane R Dowd; Paul N MacDonald
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-01       Impact factor: 4.292

3.  Characteristics of State and Federal Malpractice Litigation of Medical Liability Claims for Keratinocyte Carcinoma, 1968 to 2018.

Authors:  Raghav Tripathi; Harib H Ezaldein; Krithika Rajkumar; Jeremy S Bordeaux; Jeffrey F Scott
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

4.  Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry.

Authors:  Lindy Paulina Johanna Arts; Rick Waalboer-Spuij; Kees-Peter de Roos; Monique R T M Thissen; Luc J Scheijmans; Mieke J Aarts; Simone Oerlemans; Marnix L M Lybeert; Marieke W J Louwman
Journal:  Dermatology       Date:  2019-08-21       Impact factor: 5.366

Review 5.  Sun protection for preventing basal cell and squamous cell skin cancers.

Authors:  Guillermo Sánchez; John Nova; Andrea Esperanza Rodriguez-Hernandez; Roger David Medina; Carolina Solorzano-Restrepo; Jenny Gonzalez; Miguel Olmos; Kathie Godfrey; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2016-07-25

6.  Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial.

Authors:  Martin A Weinstock; Kachiu C Lee; Mary-Margaret Chren; Kimberly Marcolivio
Journal:  J Am Acad Dermatol       Date:  2009-04-26       Impact factor: 11.527

7.  Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis.

Authors:  Tara I Ellison; Molly K Smith; Anita C Gilliam; Paul N MacDonald
Journal:  J Invest Dermatol       Date:  2008-05-29       Impact factor: 8.551

8.  A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.

Authors:  Anna Mandinova; Vihren Kolev; Victor Neel; Bing Hu; Wesley Stonely; Jocelyn Lieb; Xunwei Wu; Claudia Colli; Rong Han; Michael J Pazin; Mike Pazin; Paola Ostano; Reinhard Dummer; Janice L Brissette; G Paolo Dotto
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

9.  An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.

Authors:  Carlos Caulin; Thao Nguyen; Gene A Lang; Thea M Goepfert; Bill R Brinkley; Wei-Wen Cai; Guillermina Lozano; Dennis R Roop
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  p53, chemokines, and squamous cell carcinoma.

Authors:  David M Owens
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.